Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:16 PM ET 8-K/A
Nasdaq/NYSE Compliance Notice Better Home & Finance Holding Co BETR

Better Home & Finance Holding Nasdaq/NYSE Compliance Notice

Better Home & Finance Holding Company received a formal notice from Nasdaq on October 13, 2026, stating it is no longer in compliance with independent director and audit committee requirements following recent board resignations. The company has until November 27, 2026, to submit a plan to regain compliance, which if accepted, could grant an extension of up to 180 days to meet listing standards.

Counterparty
Nasdaq
Term
45 days
4:09 PM ET 8-K/A
M&A Deal Watsco Inc WSO

Watsco Signs $505M M&A Deal with Granite Group Holdings LLC

Watsco, Inc. completed the acquisition of Granite Group Holdings LLC, a Northeast distributor of plumbing and HVAC products, for $505 million. The consideration was paid as 80% cash and 20% in common stock, resulting in the issuance of 338,176 shares at the closing on October 9, 2026.

Value
$505M
Counterparty
Granite Group Holdings LLC
3:50 PM ET 8-K
Nasdaq/NYSE Compliance Notice Netcapital Inc. NCPL

Netcapital Nasdaq/NYSE Compliance Notice

Netcapital Inc. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its stock price remained at or above that level for 10 consecutive business days. However, the company remains non-compliant regarding delinquent periodic reports (Form 10-K and 10-Q) and has engaged Adeptus Partners, LLC as its new independent auditor to address these filings.

Counterparty
The Nasdaq Stock Market LLC
3:32 PM ET 8-K
M&A Deal Clear Channel Outdoor Holdings, Inc. CCO

Clear Channel Outdoor Holdings Signs $6.2B M&A Deal with Mubadala Capital

Clear Channel Outdoor Holdings, Inc. completed its acquisition by Mubadala Capital in a transaction valued at approximately $6.2 billion. As a result of the merger, the company has become a wholly owned subsidiary of Madison Parent Inc. and its common stock will be delisted from the New York Stock Exchange.

Value
$6.2B
Counterparty
Mubadala Capital
1:32 PM ET 8-K
Capital Raise Bbcms Mortgage Trust 2026-5C43

Bbcms Mortgage Trust 2026-5C43 Capital Raise of $989M

BBCMS Mortgage Trust 2026-5C43 entered into an underwriting agreement for the sale of $883.1 million in public commercial mortgage pass-through certificates. Additionally, the trust entered into a purchase agreement for $106.4 million in private certificates, bringing the total offering to approximately $989.5 million. The certificates are backed by a pool of commercial, multifamily, and manufactured housing community mortgage loans.

Value
$989M
Counterparty
Barclays Capital Inc.
1:04 PM ET 8-K
M&A Deal Fdctech, Inc. FDCT

Fdctech Signs $2.35M M&A Deal with Larstal Limited and Larstal Denmark ApS

FDCTech, Inc. entered into two related share purchase agreements to acquire Larstal Limited (UK) and Larstal Denmark ApS for an aggregate base purchase price of $2.35 million. Both target companies are authorized electronic money institutions regulated by the FCA in the UK and the DFSA in Denmark, respectively. The deal includes a structured payment schedule involving deposits, monthly interim payments, and a final balance due upon completion, which is subject to regulatory change-in-control approvals.

Value
$2.35M
Counterparty
Larstal Limited and Larstal Denmark ApS
12:16 PM ET 8-K/A
M&A Deal Palomino Laboratories Inc. PALX

Palomino Laboratories M&A Deal with Vega Links, Inc.

Palomino Laboratories Inc. filed an amendment to provide historical audited financial statements and pro forma financial information following its acquisition of Vega Links, Inc. The acquisition was completed via a share exchange where Palomino issued 4,472,000 shares of common stock to acquire all outstanding shares of Vega Links, making it a wholly owned subsidiary.

Counterparty
Vega Links, Inc.
12:14 PM ET 8-K
M&A Deal Valaris Ltd VAL

Valaris M&A Deal with Transocean Ltd.

Valaris Limited and Transocean Ltd. received unconditional clearance from the Brazilian competition authority (CADE) for their pending business combination. This marks the satisfaction of the final regulatory approval condition, with the merger expected to close in the fourth quarter of 2026 following a fifteen-day waiting period.

Counterparty
Transocean Ltd.
11:14 AM ET 8-K
Capacity Expansion American Rebel Holdings Inc AREB

American Rebel Holdings Capacity Expansion

American Rebel's subsidiary, Champion Safe Company, is undergoing a major lean transformation and physical realignment of its Utah manufacturing facility. The initiative aims to eliminate bottlenecks, increase throughput, and create a more scalable operating platform to convert dealer demand into revenue. Management describes the project as a comprehensive factory redesign that goes beyond moving equipment to fundamentally improve production flow and efficiency.

9:26 AM ET 8-K
M&A Deal StageWise Strategies Corp. TEGO

StageWise Strategies M&A Deal with Teg SPV LLC

StageWise Strategies Corp. completed a share exchange transaction to acquire 99.99% of TEG SPV LLC, an Uzbekistan-based entity, in exchange for 183,098,434 shares of common stock. Following the closing, TEG SPV became a subsidiary of the company, representing approximately 97.3% of the post-transaction outstanding shares. The company also changed its name to TEG Overseas, Inc. as part of the transaction.

Counterparty
TEG SPV LLC
9:16 AM ET 8-K
M&A Deal Gemini Space Station, Inc. GEMI

Gemini Space Station M&A Deal Update

Gemini Space Station, Inc. filed a prospectus supplement to register the potential resale of up to 7,142,857 shares of Class A common stock by an unnamed investor. The company receives no proceeds from these sales as they are secondary offerings by the selling stockholder, typically following a prior issuance such as an acquisition or private placement.

9:01 AM ET 8-K
Divestiture Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Divestiture for $203M

Ultragenyx Pharmaceutical Inc. entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. The PRV was recently awarded by the FDA following the approval of FAYUVI (UX111) for the treatment of Sanfilippo syndrome Type A. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.

Value
$203M
9:01 AM ET 8-K
M&A Deal Liberty Global Ltd. LBTYA

Liberty Global M&A Deal with DigitalBridge, TD Greystone Infrastructure and L&G

Liberty Global received EU Commission clearance for the previously announced sale of VodafoneZiggo's passive tower assets for €669 million. The transaction is part of a broader strategy to dispose of €1.2-1.4 billion in non-core assets to support the planned spin-off and listing of Ziggo Group in Amsterdam in 2027.

Counterparty
DigitalBridge, TD Greystone Infrastructure and L&G
9:00 AM ET 8-K
M&A Deal Skyx Platforms Corp. SKYX

Skyx Platforms Signs $12.5M M&A Deal with Deako, Inc.

SKYX Platforms Corp. completed its acquisition of Deako, Inc., which became a wholly-owned subsidiary. The consideration consisted of 25,000,000 shares of common stock, $4 million in cash, and an $8.5 million senior secured promissory note. Deako's former shareholders now own approximately 15.6% of the combined company.

Value
$12.5M
Counterparty
Deako, Inc.
8:52 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced it will present data on its multispecific platform and CD40-directed portfolio at the SITC 2026 Annual Meeting. The presentation will focus on the platform's ability to coordinate innate and adaptive immune activity within the tumor microenvironment to overcome immunosuppression in solid tumors.

Counterparty
Society for Immunotherapy of Cancer (SITC)
8:47 AM ET 8-K
M&A Deal Integer Holdings Corp ITGR

Integer Holdings M&A Deal with Kohlberg Kravis Roberts & Co. L.P.

Integer Holdings Corporation provided a status update on its pending acquisition by affiliates of KKR, noting that a special meeting of stockholders to approve the merger is scheduled for October 21, 2026. The company also disclosed that it has received several stockholder complaints and demand letters alleging disclosure deficiencies in its proxy statement and has issued supplemental disclosures to address these claims.

Counterparty
Kohlberg Kravis Roberts & Co. L.P.
8:43 AM ET 8-K
Partnership Pulse Biosciences, Inc. PLSE

Pulse Biosciences Partnership with Clayman Thyroid Center at the Hospital for Endocrine Surgery

Pulse Biosciences has entered into a commercial and clinical partnership with the Clayman Thyroid Center to utilize the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules. The collaboration involves the commercial use of the system at the Tampa-based center and a joint effort to collect real-world clinical outcomes and conduct formal studies on nsPFA energy utility.

Counterparty
Clayman Thyroid Center at the Hospital for Endocrine Surgery
8:35 AM ET 8-K
Product Launch Data443 Risk Mitigation, Inc. ATDS

Data443 Risk Mitigation Product Launch

Data443 Risk Mitigation, Inc. announced the general availability of Vaikora, its AI runtime enforcement and control platform designed to govern AI agent actions and data flows in real-time. The platform provides inline controls to allow, block, or constrain AI tool calls and agent-to-agent communications, addressing a security gap as enterprises move autonomous AI agents into production.

8:35 AM ET 8-K
Research Collaboration Vir Biotechnology, Inc. VIR

Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B

Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.

Value
$1.88B
Counterparty
Gilead Sciences, Inc.
8:13 AM ET 8-K
M&A Deal Flex Ltd. FLEX

Flex Signs $1.1B M&A Deal with EPC Power Corp.

Flex Ltd. completed its acquisition of EPC Power Corp., a provider of power conversion solutions for data centers and grid applications, to strengthen its Cloud and Power Infrastructure portfolio. To fund the transaction, Flex entered into a $1.1 billion senior bridge credit facility and borrowed the full amount on October 14, 2026. The acquisition is part of Flex's strategy to address AI infrastructure power demands ahead of its planned spin-off of the segment into a new company, Axiom Solutions International, Inc.

Value
$1.1B
Counterparty
EPC Power Corp.

“EPC Power adds differentiated power conversion and grid-forming technology to our capabilities across power, cooling and compute. Together, we can help customers address the growing power demands of AI infrastructure with more efficient, resilient and integrated solutions.”

Revathi Advaithi, Chief Executive Officer of Flex
8:00 AM ET 8-K
Clinical Trial Data Profound Medical Corp. PROF

Profound Medical Clinical Trial Data

Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.

Counterparty
Mayo Clinic
8:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice OneMedNet Corp ONMD

OneMedNet Nasdaq/NYSE Compliance Notice

OneMedNet Corporation has regained compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from September 29, 2026, through October 12, 2026. Nasdaq has officially closed the matter, resolving the deficiency notice originally issued on April 14, 2026.

Counterparty
Nasdaq
8:00 AM ET 8-K
Contract Win Fermi Inc. FRMI

Fermi Wins $6.5B Contract from TensorWave

Fermi Inc. entered into a binding 15-year turnkey lease agreement with TensorWave for 222 MW of total power capacity at its Project Matador site. The contract is expected to generate $6.5 billion in revenue over the initial term and includes investment-grade credit support from AMD. Phased delivery of the capacity is scheduled to begin in Q4 2027 and complete in early 2028.

Value
$6.5B
Counterparty
TensorWave
Term
15 years
7:59 AM ET 8-K
Capital Raise Strive, Inc. ASST

Strive Capital Raise of $369M

Strive, Inc. announced the exercise of 273,493,909 traditional warrants between October 12 and October 13, 2026, resulting in the issuance of 13,674,703 shares of Class A common stock for gross proceeds of $369.2 million. Following these exercises, no warrants from the company's PIPE transaction remain outstanding. Additionally, the company disclosed the purchase of 2,822 bitcoin for approximately $235 million during the same period.

Value
$369M
7:52 AM ET 8-K
Clinical Trial Data Entrada Therapeutics, Inc. TRDA

Entrada Therapeutics Clinical Trial Data

Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.

7:45 AM ET 8-K
Nasdaq/NYSE Compliance Notice Brightline Interactive, Inc. BTLN

Brightline Interactive Nasdaq/NYSE Compliance Notice

Brightline Interactive regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days. The company achieved this by implementing a 1-for-8 reverse stock split effective September 28, 2026, following a prior delisting notice. The matter is now closed and the company's stock continues to trade on the Nasdaq Capital Market under the symbol BTLN.

Counterparty
The Nasdaq Stock Market LLC
7:33 AM ET 8-K
Divestiture Faraday Future Intelligent Electric Inc. FFAI

Faraday Future Intelligent Electric Divestiture to FF EAI Robotics Ecosystem Inc. for $200M

Faraday Future Intelligent Electric Inc. (FFAI) entered into a definitive agreement to sell its robotics business to FF EAI Robotics Ecosystem Inc. (FFR) for an aggregate consideration of approximately $200 million. The transaction is an all-stock deal where FFAI will receive FFR common and preferred stock, resulting in FFAI holding a 65.7% controlling interest in FFR upon closing. The deal allows FFAI to monetize its robotics assets while maintaining majority control of the newly pure-play robotics entity.

Value
$200M
Counterparty
FF EAI Robotics Ecosystem Inc. (FFR)
7:32 AM ET 8-K
M&A Deal FF EAI Robotics Ecosystem Inc. FFR

FF EAI Robotics Ecosystem Signs $200M M&A Deal with Faraday Future Intelligent Electric Inc.

FF EAI Robotics Ecosystem Inc. entered into a definitive transaction agreement to acquire the robotics business of its majority stockholder, Faraday Future Intelligent Electric Inc. (FFAI), for approximately $200 million. The all-stock deal involves the issuance of common and preferred shares at a valuation of $2.246 per share, making the company a pure-play humanoid and bionic robotics entity. The transaction is expected to close by the end of October 2026, resulting in FFAI holding approximately 65.7% of the combined company.

Value
$200M
Counterparty
Faraday Future Intelligent Electric Inc.
7:21 AM ET 8-K
Licensing Deal Aquestive Therapeutics, Inc. AQST

Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M

Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.

Value
$57.5M
Counterparty
Eton Pharmaceuticals, Inc.
Term
20 years
7:15 AM ET 8-K
M&A Deal Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.

Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.

Value
$10M
Counterparty
Aquestive Therapeutics, Inc.
Term
20 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.